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Demographic information.
Parkinson’s disease Control
Total no. 511 636
Age (years) 68.5 72.5
Age of onset (years) 61.0 Na
Female no. (%) 194 (38.0) 354 (55.7)
Early onset no. (%) 92 (18.0) Na
Heredity no. (%) 39 (7.6) Na
Na ¼ not applicable, early onset ¼ 50 years or less at diagnosis.There is an increasing evidence for genetic contribution to Par-
kinson’s disease (PD). Genes responsible for monogenetic heredi-
tary PD have been discovered to carry less devastating mutations
associated with “idiopathic” PD, suggesting that common molecu-
lar pathways are involved in the pathogenesis of monogenetic and
“idiopathic” PD. Recently, genomewide association studies (GWAS)
have revealed new PARK loci, potentially harboring genes confer-
ring an increased or decreased risk of developing PD.We have stud-
ied PARK18, for which HLA-DRA, a class II human leukocyte antigen,
was proposed as a candidate gene. Hamza et al. [1] reported that
the G allele of the single nucleotide polymorphism (SNP)
rs3129882 (A/G) in HLA-DRA, associates with increased risk for
PD in an American cohort. Attempts to replicate the association
have shown conﬂicting results [2–5]; not onlywere there lack of as-
sociations in several cohorts [2–5], but the GG genotype has also
been found to be protective [3]. Variable ﬁndings in different
studies point to the presence of geographical and ethnical differ-
ences and hence the importance of validating GWAS ﬁndings in in-
dependent homogenous case–control materials. We have
performed a replication study on the HLA-DRA SNP rs3129882 in
a homogenous Swedish case–control material in order to further
investigate the possible contribution of rs3129882 to PD.
Blood samples were collected at the Karolinska and Linköping
University Hospitals after informed consent and approval of the
RegionalEthical ReviewBoard.DNAwasobtained fromsamplesusing
standard protocols. We genotyped rs3129882 in 511 PD patients and
636 neurologically healthy controls (Table 1). A subset of the patients
(172) and controls (279) from Linköping was previously genotyped
for rs3129882 in another study [5]. Control individuals were neuro-
logically healthy spouses of patients (4%), individuals visiting hospi-
tals for non-neurological disorders (54%) and from the SNAC-K
project (The Swedish National Study on Aging and Care in Kungshol-
men http://www.snac-k.se/) (42%). All samples are unrelated Cauca-
sians from urban areas from the rather small population of Sweden,
likely to represent a homogenous case–control material. Genotyping
was performed by real-time polymerase chain reaction (PCR) (7500
fast system using standard cycling conditions, TaqMan genotyping
master mix and Genotyping Assay C_2455644_10, Applied-NC-ND license.Biosystems/Life Technologies, Carlsbad, California, USA). Due to a
non-negligible level of heterogeneity in the read-out in a subset of
the Linköping samples with lower DNA concentration, these samples
were re-sequenced with the pyrosequencing technique to conﬁrm
genotyping results. A PCR was run with Taq polymerase enzyme
and twoprimers, oneofwhichwasbiotinylatedat the 50 end (Thermo
Fisher Scientiﬁc, Ulm, Germany), (sequences are available upon
request). The PCR product was puriﬁed according to manufacturer’s
instructions, incubated with a sequencing primer and analyzed by
PYRO-sequencing (PSQ 96MA system, BIOTAGE ABUppsala, Sweden)
using PyroMark Gold Q96 Reagents (QIAGEN AB, Solna, Sweden).
Three PD patients were excluded from the analysis since they were
carriers of the pathogenic G2019S mutation LRRK2. Association was
evaluated with Chi-square (c2) and Fisher’s exact test, signiﬁcance
level 5%, two-sided P-values (GraphPad Prism 5.03, GraphPad Soft-
ware, San Diego California USA). Power and sample size software PS
3.0 was used for power analysis (http://biostat.mc.vanderbilt.edu/
wiki/Main/PowerSampleSize). With our sample size we can detect
an odds ratio of <0.712 and >1.390 with a power of 80% (a ¼ 0.05).
We genotyped a total of 511 PD patients and 636 neurologically
healthy controls from Sweden and searched for possible genotypic
and allelic association between rs3129882 and PD. Rs3129882 was
in Hardy Weinberg equilibrium for all subjects (data not shown).
We ﬁrst analyzed the entire material for which we found no geno-
typic (data not shown) or allelic association for rs3129882 and PD
(Table 2). In order to investigate variability in subgroups of pa-
tients, we stratiﬁed the material with respect to age of onset,
Table 2
Allele frequencies for rs3129882 in Parkinson’s disease patients and control subjects
analyzed with Fisher’s exact test.
PD
(no.)
Ctrl
(no.)
MAF
PD
MAF
Ctrl
P-value OR (95%CI)
Strata
Stockholm 314 206 0.425 0.422 0.91 1.02 (0.81–1.27)
Linköping 194 330 0.381 0.398 0.6 0.93 (0.72–1.2)
All subjects 508 636 0.408 0.410 0.99 1.00 (0.85–1.19)
PD-associated strata
No heredity 469 0.403 0.79 1.03 (0.87–1.22)
Familial 39 0.474 0.28 0.77 (0.49–1.22)
Late onset 414 0.402 0.77 1.03 (0.86–1.23)
Early onset 91 0.434 0.57 0.90 (0.66–1.24)
Female 193 0.402 0.81 1.03 (0.82–1.30)
Male 315 0.413 0.92 0.99 (0.81–1.20)
PD ¼ Parkinson’s disease, Ctrl ¼ controls, MAF ¼minor allele frequency, OR ¼ odds
ratio, CI ¼ conﬁdence interval.
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were compared to the whole control group since genotype and
allele frequencies were similar in the control groups (P > 0.5). Pa-
tients with maximum one ﬁrst-, second- or third-degree relative
were included in the group designated as having no known hered-
ity, while familial PD was deﬁned as patients with two or more
relatives with PD. Applying these stringent selection criteria
corresponding to those used in the report by Hamza et al. [1],
we discovered no further association for rs3129882 with PD
(Table 2).
Previous replication studies on HLA-DRA show very heteroge-
neous results [1–5]. These variations might be explained by
ancestry; allele frequencies for rs3129882 vary greatly in
different geographical regions. Hamza et al. [1] reported a signif-
icant substructure in American subjects of European decent
correlating with the country of origin of the subjects’ ancestors.
Association was stronger in subjects with ancestors from North-
ern Europe. However, no replication has yet been reported in Eu-
ropean cohorts. We found no association in our exclusively
Swedish material which is in agreement with recent ﬁndings in
a Scandinavian (Sweden, Norway) population [5]. According to
Hamza et al. [1], association was stronger in sporadic PD patients
with late onset. To mimic their study we performed an age of
onset stratiﬁed analysis, but failed to detect any further signiﬁ-
cant differences. Therefore, our results do not suggest a role for
HLA-DRA variants for PD in Sweden. Variable results in genetic
replication studies can also be explained by different Linkage
Disequilibrium (LD). Association can be found with an SNP which
is in LD with the true disease causing SNP, while in another pop-
ulation these two SNPs are not in LD. HLA genes, being closely
located on chromosome 6, could exert a joint effect. Rs3129882
is for example believed to inﬂuence expression levels of HLA-
DRA, HLA-DQA2 and HLA-DRB5 [1]. Published data on HLA-DR
associations with PD are so far more in favor of association
with HLA-DRB loci, which are also more polymorphic, than with
the rather invariable HLA-DRA.
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